Best Hospitals for ASD Closure Surgery in UAE

An Atrial Septal Defect (ASD) is a congenital cardiac anomaly characterized by a persistent opening in the interatrial septum, allowing oxygenated blood from the left atrium to shunt back into the right atrium. Over time, this left-to-right shunt causes right ventricular volume overload, progressive right heart dilation, pulmonary arterial hypertension, atrial arrhythmias, and — if left uncorrected — irreversible Eisenmenger syndrome. The four principal anatomic subtypes are: Ostium Secundum (the most common, accounting for approximately 75% of cases and the most amenable to transcatheter closure), Ostium Primum (often part of an atrioventricular septal defect), Sinus Venosus, and Coronary Sinus defects. Hemodynamic significance is determined by the Qp:Qs ratio; a ratio exceeding 1.5:1 is the internationally accepted threshold for intervention, consistent with ACC/AHA and ESC guidelines.

• ELIGIBLE PATIENTS:
• Children and adults diagnosed with hemodynamically significant Ostium Secundum ASD with a Qp:Qs ratio ≥ 1.5:1 confirmed on echocardiography or cardiac MRI
• Patients with right ventricular volume overload, right heart dilation, or exercise intolerance attributable to the ASD
• Adults presenting with cryptogenic stroke or TIA in whom paradoxical embolism through a patent ASD or large PFO is suspected
• Patients with Ostium Secundum defects ≤ 38 mm diameter with adequate septal rim tissue (≥ 5 mm on all rims except the aortic rim) for transcatheter device closure
• +20 more

ASD closure is not a single procedure — the optimal approach is individualized based on defect anatomy, patient age, body size, pulmonary hemodynamics, and the presence of associated cardiac anomalies. The following techniques represent the current spectrum of care:

1. TRANSCATHETER DEVICE CLOSURE (Preferred for Eligible Secundum ASDs) This is the first-line treatment for Ostium Secundum ASDs with adequate rim tissue and a stretched diameter ≤ 38 mm. Performed under general anesthesia or deep sedation in a hybrid catheterization laboratory, a venous sheath is advanced from the femoral vein through the inferior vena cava and across the ASD into the left atrium. A sizing balloon catheter is used to measure the stretched diameter of the defect. A self-expanding nitinol double-disc occluder — most commonly the Amplatzer Septal Occluder (ASO) or GORE CARDIOFORM device — is deployed under real-time 2D/3D transesophageal echocardiography (TEE) and fluoroscopic guidance. The device is repositioned and recaptured until optimal positioning is confirmed, then released. Complete defect closure is assessed immediately by color Doppler. The procedure typically takes 45–90 minutes. Patients are anticoagulated with unfractionated heparin intraprocedurally and maintained on aspirin (75–100 mg/day) for 6 months post-procedure, with some protocols adding clopidogrel for 3 months (dual antiplatelet therapy) during device endothelialization. Intracardiac Echocardiography (ICE) is an emerging alternative to TEE that allows the procedure to be performed under conscious sedation without general anesthesia, and is available in several advanced centers in India and the UAE.

2. MINIMALLY INVASIVE SURGICAL CLOSURE — RIGHT MINI-THORACOTOMY For patients who are not candidates for transcatheter closure (large defects, deficient rims, sinus venosus ASD with anomalous pulmonary veins, primum ASD, or failed device closure), surgical repair via a right anterolateral mini-thoracotomy (3–5 cm incision) offers excellent results with minimal scarring. Cardiopulmonary bypass is established via femoral or peripheral cannulation. The ASD is closed either by direct suture repair (for small defects) or with an autologous pericardial or synthetic (Gore-Tex/Dacron) patch for larger defects. Concurrent repair of partial anomalous pulmonary venous return (PAPVR) is performed when present. This approach avoids median sternotomy, reducing blood loss, ICU stay, and recovery time significantly compared to conventional surgery.

3. PORT-ACCESS AND ROBOTIC-ASSISTED CARDIAC SURGERY Select high-volume centers in India (Chennai, Hyderabad) and the UAE (Abu Dhabi, Dubai) offer port-access or fully robotic ASD closure using the da Vinci Surgical System. The robotic platform provides 3D magnification and articulated instrumentation through 8–12 mm ports, enabling precise suturing on the arrested heart through the lateral chest wall. This technique is particularly favored for adult patients with secundum ASDs unsuitable for transcatheter closure, offering exceptional cosmetic outcomes, minimal blood loss, shorter ICU stay (12–24 hours), and return to full activity within 3–4 weeks. It requires advanced robotic cardiac surgery expertise and appropriate patient selection (BMI, prior thoracic surgery, cardiac anatomy).

PHASE 1 — PRE-ARRIVAL & CONSULTATION (Weeks 1–2 before travel)

• GAF Healthcare coordinates a virtual second-opinion consultation between the patient/family and the treating pediatric cardiologist or cardiac surgeon at the chosen center
• All prior records (echocardiography reports, cardiac MRI, catheterization data, ECGs, blood work) are reviewed digitally
• The clinical team confirms the closure strategy (transcatheter vs. surgical) and schedules the procedure date
• GAF Healthcare initiates e-Medical Visa application for India (typically approved within 3–5 business days) or visa-on-arrival/prior visa arrangements for UAE
• Pre-procedure blood tests, infectious disease screening (HIV, HBsAg, HCV, MRSA nasal swab), and anesthesia pre-assessment forms are completed remotely where possible

PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Day 1–2)